Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
Design and Rationale of the RE‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibril
TaggedH1Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI
PCRonline - The RE-DUAL PCI trial subanalysis: In spite of... | Facebook
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial | JACC: Cardiovascular Interventions
Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review - ScienceDirect
Dual Anti-Thrombotic Therapy With Dabigatran After Percutaneous Coronary Intervention in Atrial Fibrillation - Japanese and East-Asian Subgroup Analysis of the RE-DUAL PCI Trial. | Semantic Scholar
Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy | Business Wire
Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial | SpringerLink
A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial - EuroIntervention
RE-DUAL PCI™ vs PIONEER AF-PCI™
Switching of OAC After PCI in A-fib Patients:RE-DUAL PCI Trial Subanalysis | tctmd.com
Superior safety of dual therapy with dabigatran and clopidogrel vs. triple therapy with warfarin, aspirin and clopidogrel in the RE-DUAL PCI trial: What is key, the strategy or the drug? | Semantic
The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status - tctmd.com
RE-DUAL PCI Trial: Inclusion and Main Exclusion Criteria and Study Design | Radcliffe Vascular
RE-DUAL OAC switching subanalysis animated video | boehringerone.com
Scheme of two options for antithrombotic combination therapy for... | Download Scientific Diagram
on behalf of the RE-DUAL PCI Steering Committee and Investigators - ppt download
EuroIntervention - Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial http ...
Design and Rationale of the RE‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients
